Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
LOS ANGELES, Sept. 25, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s” or the “Company”) (NYSE:RDY) for possible violations of federal securities laws between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares of Dr. Reddy’s during the Class Period should contact the firm prior to the October 24, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Dr. Reddy’s made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy’s disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, after a recent inspection of the plant. Upon release of this information to the public, shares of Dr. Reddy’s fell in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/
